age-related macular degeneration

Investigational wet AMD therapies aim for innovative targetsMany investigational drugs under development for the treatment of neovascular age-related macular degeneration (nvAMD) have advanced into the clinical trial stage, including several that are being evaluated in pivotal trials, said Peter K. Kaiser, MD.
Failed cell therapy study offers positives, raises new questionsPatients with a history of frequent anti-vascular endothelial growth factor (anti-VEGF) injections for the treatment of age-related macular degeneration (AMD) may not be the best potential candidates for encapsulated cell technology (ECT).
Mediterranean diet may protect against macular degeneration
Mediterranean diet may protect against macular degenerationThe Mediterranean diet reduces the risk of age-related macular degeneration (AMD), according to a study of two Portuguese populations.
Google DeepMind searches for signs of retinopathyGoogle is using its DeepMind computing system to search for early signs of diabetic retinopathy and neovascular age-related macular degeneration (nAMD), the company announced this month.
Pipeline for dry AMD features diverse compoundsA number of drugs are being investigated in clinical trials as treatment for slowing the growth of geographic atrophy that is secondary to age-related macular degeneration.
New prevention and monitoring strategies for neovascular AMDNutritional supplements continue to be a viable prevention strategy for neovascular age-related macular degeneration (AMD), said Emily Chew, MD.
Home-monitoring device may advance diagnostics, detection of AMDAn ophthalmologist shares the clinical benefits he has experienced with a home vision-monitoring device for his patients with age-related macular degeneration.
Investigational drug Luminate targets integrin receptorsAnti-integrin therapy is a promising new approach in the treatment of vitreoretinal disease. The first drug in this class, Allegro Ophthalmics’ Luminate, is in Phase 2 clinical trials for several indications, including wet age-related macular degeneration, diabetic macular edema, non-proliferative diabetic retinopathy, and vitreomacular traction.
Misdiagnosing macular degenerationA number of macular conditions either mimic or share characteristic findings of age-related macular degeneration (AMD). These resemblances can result in tough clinical decisions and misdiagnosis. Although genetic testing can be helpful, tests are limited by both their efficacy and accuracy.
Triple macular carotenoid supplement provides greatest benefits for AMD patientsThe AREDS2 findings have empowered ophthalmologists to recommend appropriate supplements to reduce risk of visual loss in patients with AMD. In this article, the authors discuss the emerging revelation that the constituents of macular pigment enhance visual performance and explain how supplementation with all three macular carotenoids in a MZ:L:Z (mg) ratio of 10:10:2 can confer the greatest benefits.